Acteoside (verbascoside)

Acteoside, also called verbascoside, is a phenylpropanoid glycoside composed of caffeic acid, hydroxytyrosol, and two sugar moieties found in numerous medicinal plants. It exerts its primary effects through inhibition of protein kinase C and modulation of MAPK signaling pathways, contributing to anti-inflammatory and cytoprotective activity.

Origin & History

Acteoside (verbascoside) is a polyphenol glycoside composed of caffeic acid and hydroxytyrosol, with a molecular weight of 624.6 g/mol. It occurs naturally in various plants such as Verbascum species, from which it derives its alternate name verbascoside. The compound is typically extracted from plant sources, though specific extraction methods are not detailed in available research.

Historical & Cultural Context

No information on traditional medicine use or historical applications of acteoside is available in the current research. The compound's name derives from Verbascum species plants, but traditional usage patterns are not documented.

Health Benefits

• Antimicrobial activity: Demonstrates effectiveness against Staphylococcus aureus and other bacteria (MIC 4-128 μg/ml) - preliminary evidence
• Anti-inflammatory properties: Acts as a protein kinase C inhibitor (IC50 25 μM) - preliminary evidence
• Potential cellular protection: May influence MAPK/ERK and NF-κB pathways - preliminary evidence only
• Antibacterial spectrum: Shows activity against both Gram-positive and Gram-negative bacteria - in vitro studies
• Possible immune modulation: PKC inhibition suggests immune regulatory potential - mechanistic data only

How It Works

Acteoside inhibits protein kinase C (PKC) with an IC50 of approximately 25 μM, disrupting downstream phosphorylation cascades involved in inflammatory gene expression. It also modulates mitogen-activated protein kinase (MAPK) pathways, including ERK and p38 signaling, which regulate cellular stress responses and apoptosis. Additionally, its caffeic acid moiety contributes to free radical scavenging activity, reducing oxidative damage to lipids and proteins.

Scientific Research

The available research on acteoside lacks human clinical trials, randomized controlled trials, or meta-analyses. Current evidence is limited to in vitro studies demonstrating antimicrobial and anti-inflammatory properties through protein kinase C inhibition.

Clinical Summary

Research on acteoside remains largely preclinical, with most evidence derived from in vitro cell assays and rodent models rather than human clinical trials. Antimicrobial studies report minimum inhibitory concentrations (MIC) of 4–128 μg/ml against Staphylococcus aureus and related pathogens, depending on the bacterial strain and preparation. Animal studies have demonstrated reductions in inflammatory markers such as TNF-α and IL-6, though dose translation to humans remains uncertain. No large-scale randomized controlled trials have been completed as of current literature, making all therapeutic claims preliminary.

Nutritional Profile

Acteoside (verbascoside) is a phenylpropanoid glycoside (phenylethanoid glycoside) and not a conventional food nutrient, so it does not contribute macronutrients, vitamins, or minerals in a dietary sense. Molecular weight: 624.59 g/mol. Chemical formula: C29H36O15. It is a secondary plant metabolite found at varying concentrations depending on source plant: approximately 0.1–3.5% dry weight in Verbascum species, 0.5–2% in Olea europaea leaves, up to 4% in Cistanche tubulosa (a concentrated medicinal source), and trace amounts (0.01–0.5%) in common herbs such as oregano and rosemary. As a glycoside, it consists of a hydroxytyrosol unit linked to caffeic acid and two sugar moieties (rhamnose and glucose), contributing to its polyphenolic antioxidant character. ORAC-equivalent antioxidant capacity is high relative to molecular weight, with free radical scavenging IC50 values reported at approximately 2–8 μM in DPPH assays. Bioavailability is limited due to glycoside hydrolysis in the gut; oral bioavailability in animal models is estimated at 1–5% of ingested dose, with metabolites including hydroxytyrosol and caffeic acid detectable in plasma. It is not a source of dietary fiber, protein, fat, or micronutrients. Studied doses in research contexts range from 10–100 mg/kg in animal models; human clinical dose equivalents are not firmly established.

Preparation & Dosage

No clinically studied dosage ranges are available for acteoside in any form (extract, powder, or standardized preparations). Human dosing protocols have not been established through clinical research. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Other polyphenols, caffeic acid derivatives, hydroxytyrosol, plant glycosides, anti-inflammatory herbs

Safety & Interactions

Acteoside has demonstrated a generally favorable safety profile in animal toxicity studies at typical experimental doses, but human safety data are limited. Because it inhibits protein kinase C, caution is theoretically warranted when combining it with immunosuppressant drugs or kinase-targeting pharmaceuticals, as additive or antagonistic effects are possible. Pregnant and breastfeeding individuals should avoid supplementation due to the absence of safety data in these populations. Individuals taking anticoagulant medications should exercise caution, as the caffeic acid component may have mild platelet-affecting properties.